Castle Biosciences, Inc.
NASDAQ: CSTL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Derek J. Maetzold
- Employees
- 784
- Headquarters
- Friendswood, United States
- IPO year
- 2019
- Market cap
- $670.9M
- Website
- https://castlebiosciences.com
Loading CSTL…
Loading profile data…Frequently asked questions about CSTL
What does Castle Biosciences, Inc. (CSTL) do?
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineer...
Where does CSTL trade?
Castle Biosciences, Inc. (CSTL) trades on the NASDAQ Global Market.
What sector is CSTL in?
Castle Biosciences, Inc. (CSTL) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Castle Biosciences, Inc.?
Derek J. Maetzold is the chief executive officer of Castle Biosciences, Inc. (CSTL).
Where is Castle Biosciences, Inc. headquartered?
Castle Biosciences, Inc. is headquartered in United States.
Does CSTL pay a dividend?
Castle Biosciences, Inc. (CSTL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CSTL go public?
Castle Biosciences, Inc. (CSTL) completed its initial public offering in 2019.